Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling
- 1 May 2020
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (13) , 1389-1397
Abstract
PURPOSE A powerful consequence of detecting cancer-associated pathogenic variants is the ability to test at-risk relatives (ARRs), termed cascade testing. However, historical studies suggest cascade testing uptake of 30% or less. Here, we tested the feasibility of a novel, streamlined method of cascade testing using telephone genetic counseling and mailed saliva-based genetic testing. PATIENTS AND METHODS: Probands with newly diagnosed cancer-associated pathogenic variants were offered facilitated cascade testing whereby the genetics team identified and contacted ARRs by telephone to disclose the familial pathogenic variant and offer telephone counseling and mailed saliva testing. Results and guideline-based recommendations were reviewed by telephone and shared with the primary care physician. RESULTS: Thirty probands were enrolled, and 114 ARRs were identified. Twelve ARRs were excluded (lived outside of the United States, n = 5; proband did not approve of contact, n = 7). Among 102 ARRs telephoned, contact was established with 95 (93%). Among 114 identified ARRs, 66 (58%) completed genetic testing. Among those completing testing, 27 (41%) carried the familial pathogenic variant. Surveys of ARRs at the time of genetic testing and 6 months later demonstrated low levels of anxiety, depression, distress, and uncertainty and high levels of satisfaction with testing. At 6 months, 7 ARRs with pathogenic variants had undergone cancer surveillance interventions and 4 had undergone cancer risk-reducing surgery. CONCLUSION: Facilitated cascade testing with telephone genetic counseling and mailed saliva kits resulted in high testing uptake among ARRs. Positive genetic testing resulted in utilization of genetically targeted primary disease prevention at short-term follow-up. Facilitated cascade testing is a straightforward, low-cost, easily implemented strategy with significant potential to promote early detection for affected ARRs and reduce cancer mortality and should be evaluated in larger scale clinical trials.Keywords
This publication has 28 references indexed in Scilit:
- The Search for Unaffected Individuals with Lynch Syndrome: Do the Ends Justify the Means?Cancer Prevention Research, 2011
- Comparison of proactive and usual approaches to offering predictive testing for BRCA1/2 mutations in unaffected relativesClinical Genetics, 2009
- Increased genetic counseling support improves communication of genetic information in familiesGenetics in Medicine, 2008
- Letting the family know: balancing ethics and effectiveness when notifying relatives about genetic testing for a familial disorderJournal of Medical Genetics, 2006
- Cascade testing in familial hypercholesterolaemia: how should family members be contacted?European Journal of Human Genetics, 2005
- Testing Participation in BRCA1/2 -Positive Families: Initiator Role of Index CasesGenetic Testing, 2003
- A brief assessment of concerns associated with genetic testing for cancer: The multidimensional impact of cancer risk assessment (MICRA) questionnaire.Health Psychology, 2002
- A brief assessment of concerns associated with genetic testing for cancer: The multidimensional impact of cancer risk assessment (MICRA) questionnaire.Health Psychology, 2002
- Patient Satisfaction with Health Care DecisionsMedical Decision Making, 1996
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983